What Is the Average Weight Loss with Mounjaro?

Last reviewed: July 15, 2026

Last updated: July 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, the active ingredient in Mounjaro, has become one of the most studied GLP-1 receptor agonist and GIP receptor agonist combination therapies for weight loss. In landmark clinical trials, participants achieved an average weight loss of 21% of their baseline body weight over 68 weeks—a significant result that has reshaped expectations for medical weight management. PlexusDx offers compounded tirzepatide injection at $289/mo month-to-month, or from $249/mo on the 6-month plan from licensed 503A compounding pharmacies, making this dual-action therapy accessible across all 50 states without insurance requirements.

Clinical Trial Weight Loss Results with Tirzepatide

The SURMOUNT clinical trial program evaluated tirzepatide's effectiveness across multiple cohorts. In SURMOUNT-1, patients receiving the highest dose of tirzepatide lost an average of 21% of their starting body weight over 68 weeks of treatment. Comparatively, patients on placebo lost only 2.6% of their body weight during the same period. These results represent a sustained, clinically meaningful reduction that persists for as long as the medication is continued.

Weight loss with tirzepatide occurs in two distinct phases. The first phase, typically lasting 4–12 weeks, involves rapid appetite suppression as the medication reaches therapeutic levels in your body. The second phase extends over months 3–12, where steady, consistent weight loss continues as your body adapts to reduced calorie intake and improved metabolic function. Most patients experience noticeable changes within the first month, though full results develop gradually over the treatment course.

How Individual Factors Affect Your Weight Loss Timeline

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Diet quality and physical activity level significantly amplify tirzepatide's effects. Patients who combine medication with consistent protein intake, whole foods, and regular movement see greater weight loss than those relying solely on appetite suppression. The medication acts as a tool that reduces hunger signals and improves satiety, but sustainable loss still requires conscious nutrition choices. Additionally, sleep duration, stress management, and hydration status indirectly influence metabolic response and the rate at which your body mobilizes stored fat.

Timeline for Seeing Weight Loss on Tirzepatide

Weeks 1–4: Initial dose typically begins at 2.5 mg weekly. Many patients report reduced appetite and food cravings within 3–7 days, though the scale may not reflect significant losses. Some people lose 2–5 pounds in the first two weeks due to reduced water retention and decreased caloric intake. Expectations should emphasize that appetite control precedes visible weight loss.

Weeks 5–12: As your body adjusts and doses escalate (usually to 5 mg), weight loss accelerates. Most patients report losing 5–15 pounds by the end of week 12, with more consistent daily appetite suppression. Energy levels often stabilize, and clothing fit begins to change noticeably. Weeks 13–68: Continued dose increases (up to 15 mg based on tolerance and response) produce steady weekly losses of 0.5–2 pounds. The majority of total weight loss occurs between months 3 and 9, with losses tapering slightly as you approach your goal weight.

Comparing Tirzepatide to Other GLP-1 Therapies

Tirzepatide's dual-action mechanism—stimulating both GLP-1 and GIP receptors—produces greater weight loss than single-agent GLP-1 medications like semaglutide. In head-to-head trials, tirzepatide users lost 4–7% more body weight than semaglutide users at equivalent treatment durations. This superior efficacy comes from tirzepatide's ability to influence both appetite centers and glucose metabolism simultaneously, creating a more comprehensive physiologic response. PlexusDx offers both compounded semaglutide (at $189/mo month-to-month, or from $149/mo on the 6-month plan injection) and tirzepatide (at $289/mo month-to-month, or from $249/mo on the 6-month plan injection), allowing your prescribing clinician to select the agent best suited to your genetic profile and medical history.

For patients seeking maximum impact, PlexusDx's GLP-Squared Injection combines compounded semaglutide and tirzepatide in one formulation, at $289/mo month-to-month, or from $249/mo on the 6-month plan. This dual-compound approach appeals to individuals with complex metabolic profiles or those who have plateaued on single-agent therapy. Oral formulations of both semaglutide and tirzepatide are available for patients who prefer pills over injections, though injection forms generally achieve faster and more consistent therapeutic levels.

Sustaining Weight Loss After Reaching Your Goal

Weight loss sustainability on tirzepatide depends on continuing the medication and maintaining the lifestyle habits you've developed during treatment. Clinical data shows that patients who discontinue tirzepatide tend to regain weight within 12 months, though the rate varies. Those who sustain diet improvements and activity levels regain less weight than those who revert to pre-treatment eating patterns. Tirzepatide appears to work best as a long-term therapy rather than a short-term intervention—similar to how blood pressure or diabetes medications require ongoing use to maintain benefit.

Many patients benefit from periodic dose adjustments or maintenance scheduling to optimize their long-term results. PlexusDx's straightforward monthly pricing model ($289/mo for tirzepatide injection across all dose levels) removes cost barriers to continued access and dosage optimization. Adding the Precision Peptide Genetic Test ($99 one-time add-on after your first month) helps refine your long-term protocol by identifying your genetic strengths in appetite regulation and metabolic pathways—knowledge that improves clinician decision-making about whether to maintain, adjust, or combine your tirzepatide with complementary therapies.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I realistically expect to lose with tirzepatide in my first month?

Most patients lose 2–8 pounds in month one, with the majority of loss coming from appetite reduction and decreased water retention rather than fat mobilization. The first month establishes your body's tolerance to the medication; more substantial losses occur in months 2–6. Individual outcomes depend on your starting weight, baseline metabolism, and how strictly you follow dietary guidance.

Why do some people lose more weight with tirzepatide than others?

Genetic variations in appetite-control genes (GLP1R, GIPR) and metabolic genes (FTO, MC4R) influence how effectively tirzepatide signals satiety in your brain and how your body burns calories. PlexusDx's Precision Peptide Genetic Test identifies these variants across 14 metabolic pathways, explaining 60–80% of the variation in individual weight loss response. Combined with lifestyle consistency and starting body composition, genetics play a measurable role in outcomes.

Does tirzepatide from PlexusDx work the same as brand-name Mounjaro?

PlexusDx's compounded tirzepatide contains the identical active pharmaceutical ingredient as Mounjaro, produced by licensed 503A compounding pharmacies under strict quality standards. The primary difference is cost—PlexusDx charges $289/mo flat for tirzepatide injection regardless of dose, whereas brand-name Mounjaro often requires insurance or costs significantly more out-of-pocket. Efficacy and safety profiles are equivalent when compounded to pharmaceutical grade.

What happens to weight loss if I take tirzepatide inconsistently?

Tirzepatide requires consistent weekly dosing for optimal appetite suppression and metabolic effect. Skipped or delayed doses reduce the medication's continuous action on hunger signals, typically resulting in slower or stalled weight loss during those weeks. Patients who maintain adherence lose weight steadily; those with gaps experience plateaus or slight regains. Setting weekly injection reminders and keeping your medication easily accessible improves adherence and outcomes.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

PlexusDx's Precision Peptide Genetic Test analyzes key variants linked to appetite hormone responsiveness and metabolic efficiency, providing insight into your biological predisposition to tirzepatide benefit. Patients with favorable GLP1R and GIPR variants often experience more robust appetite suppression, while those with specific FTO or MC4R variants may need higher doses or lifestyle optimization to achieve target losses. Knowing your genetic profile helps your clinician set realistic expectations and personalize your protocol.

Related Reading

• Average Weight Loss On Ozempic
• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.